| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JTHO.2016.11.2231 |
| P8608 | Fatcat ID | release_7drq4uvenfhblm2vis5tih4deu |
| P698 | PubMed publication ID | 27923714 |
| P50 | author | Chong-Jen Yu | Q42255080 |
| Wei-Yu Liao | Q57020031 | ||
| P2093 | author name string | Jin-Yuan Shih | |
| James Chih-Hsin Yang | |||
| Chao-Chi Ho | |||
| Chih-An Lin | |||
| P433 | issue | 3 | |
| P304 | page(s) | 567-572 | |
| P577 | publication date | 2016-12-05 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib | |
| P478 | volume | 12 |
| Q91762027 | A "triple whammy" in adenocarcinoma lung |
| Q92915641 | Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers |
| Q90009683 | Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion |
| Q92111772 | Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers |
| Q91965065 | Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report |
| Q90727978 | Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib |
| Q92354801 | Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors |
| Q49643911 | Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. |
| Q90239889 | Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer |
| Q91995280 | Covalent Inhibition in Drug Discovery |
| Q41472663 | EGFR G796D mutation mediates resistance to osimertinib |
| Q64089193 | Emerging therapies for non-small cell lung cancer |
| Q39415339 | Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis |
| Q45983599 | Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. |
| Q97538360 | Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer |
| Q98466270 | Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports |
| Q99589746 | M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib-resistant cell lines HCC827/GR |
| Q47547443 | MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib |
| Q59800637 | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy |
| Q47146662 | Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer |
| Q60301224 | Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report |
| Q47730834 | Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? |
| Q38598893 | Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy |
| Q47777525 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study |
| Q91637200 | Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis |
| Q98386351 | Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis |
| Q57177486 | Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective |
| Q52589214 | RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade. |
| Q90352700 | Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer |
| Q91632717 | Targeting Alterations in the RAF-MEK Pathway |
| Q93018599 | The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients |
| Q100636214 | The next tier of EGFR resistance mutations in lung cancer |
| Q49887956 | Third generation EGFR TKIs: current data and future directions |
| Q33740707 | Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer |
| Q99418035 | Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer |
| Q47141830 | Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. |
| Q50104127 | Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer |
| Q49300205 | Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors |
| Q46915997 | Understanding and targeting resistance mechanisms in NSCLC. |
| Q92642152 | Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy |
| Q91865052 | Update on liquid biopsy in clinical management of non-small cell lung cancer |
| Q51741619 | [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer]. |
Search more.